Structure and Activity of (2,8)-Dicarba-(3,12)-cystino α-ImI, an α-Conotoxin Containing a Nonreducible Cystine Analogue-Reference-Cited by-同舟云学术

Structure and Activity of (2,8)-Dicarba-(3,12)-cystino α-ImI, an α-Conotoxin Containing a Nonreducible Cystine Analogue

Published:2009-01-06 Issue:3 Volume:52 Page:755-762
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

MacRaild Christopher A.¹,Illesinghe Jayamini¹,Lierop Bianca J. van¹,Townsend Amanda L.¹,Chebib Mary¹,Livett Bruce G.¹,Robinson Andrea J.¹,Norton Raymond S.¹

Affiliation:

1. The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Victoria, Australia, School of Chemistry, Monash University, Clayton 3800, Victoria, Australia, Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Parkville 3010, Australia, Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm8011504

Reference39 articles.

1. Conotoxins down under

2. α-Conotoxins as selective probes for nicotinic acetylcholine receptor subclasses

3. Drugs from the Sea: Conopeptides as Potential Therapeutics

4. α-Selenoconotoxins, a New Class of Potent α7 Neuronal Nicotinic Receptor Antagonists

5. Synthesis of a biologically active analog of deamino-8-arginine-vasopressin which does not contain a disulphide bond

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, conformational analysis, and biological activity of Cα ¹ -to-Cα ⁶ 1,4- and 4,1-disubstituted 1 H -[1,2,3]triazol-1-yl-bridged oxytocin analogues;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-09-21

2. Synthesis of disulfide surrogate peptides incorporating an ethylene glycol bridge;New Journal of Chemistry;2023

3. Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75;Frontiers in Pharmacology;2022-11-02

4. Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection;Frontiers in Pharmacology;2022-10-19

5. Discovery of Methylene Thioacetal-Incorporated α-RgIA Analogues as Potent and Stable Antagonists of the Human α9α10 Nicotinic Acetylcholine Receptor for the Treatment of Neuropathic Pain;Journal of Medicinal Chemistry;2021-06-23